Odyssey Therapeutics, Inc.
ODTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ODTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ODTX
Odyssey Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing immunology therapeutics, with its two most advanced programs, OD-001 and OD-002, in phase 2a clinical trials and IND-enabling studies, respectively.
Key risk: No approved products or revenue
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Odyssey Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing immunology therapeutics, with its two most advanced programs, OD-001 and OD-002, in phase 2a clinical trials and IND-enabling studies, respectively.
- Odyssey Therapeutics is a clinical-stage biotechnology company formed in April 2021, focused on immunology [sec · filed 2026-04-17].
- The company's two most advanced programs are OD-001 (phase 2a clinical trial) and OD-002 (IND-enabling studies) [sec_mda · as of 2026-04-17].
- As of June 30, 2026, the company reported cash and equivalents of $85.5M, zero revenue, a net loss of -$52.8M, and negative shareholders' equity of -$382.5M [sec].
- The company has a history of incurring substantial net losses, no products approved for commercial sale, and has never generated revenue from product sales [sec · filed 2026-04-17].
- Odyssey expects expenses to increase substantially as it progresses OD-001, OD-002, and other target selection programs [sec · filed 2026-04-17].
What works
- The company leverages deep knowledge of human immune biology and a target selection approach that prioritizes well-characterized biology supported by clinical or translational evidence and human genetics [sec · filed 2026-04-17].
- Odyssey has internal capabilities to determine the optimal modality (small molecule or protein therapeutic) for drugging core biology [sec · filed 2026-04-17].
What to weigh
- The company has a limited operating history (formed April 2021), no approved products, and has never generated revenue from product sales [sec · filed 2026-04-17].
- Odyssey has incurred substantial net losses and expects to continue incurring significant losses for the foreseeable future, with losses increasing as development progresses [sec · filed 2026-04-17].
- The company will require substantial additional capital to finance operations, and if unable to raise it, may be forced to delay, reduce, or eliminate programs [sec · filed 2026-04-17].
- The most advanced product candidate (OD-001) is only in a phase 2a trial, and the company has never completed large-scale or pivotal clinical trials [sec_mda · as of 2026-04-17].
From the filings
Quoted directly from source documents.
Odyssey is a clinical-stage biotechnology company with a limited operating history and no approved products.
“We are a clinical-stage biotechnology company with a limited operating history. We were formed in April 2021 and have devoted substantially all of our resources since that time to research and development activities for our product candidates, including OD-001 and OD-002”
SEC filings · April 17, 2026
The company's two most advanced programs are OD-001 (phase 2a) and OD-002 (IND-enabling).
“Our two most advanced product candidates are currently in a phase 2a clinical trial and IND-enabling studies, respectively.”
SEC MD&A · April 17, 2026
The company has never generated revenue from product sales and may never be profitable.
“have no products approved for commercial sale, have never generated revenue from product sales and may never be profitable.”
SEC filings · April 17, 2026
The company expects expenses to increase substantially as it progresses its programs.
“We expect our expenses will increase substantially in connection with our ongoing and planned activities, as we: • continue to progress the development of our product candidates, including our two most advanced programs: OD-001 and OD-002”
SEC filings · April 17, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Odyssey has no products approved for commercial sale and has never generated revenue from product sales [sec · filed 2026-04-17].
- Substantial capital needs — The company will require substantial additional capital to finance operations; failure to raise it may force delays or program reductions [sec · filed 2026-04-17].
- Early-stage pipeline — The most advanced candidate (OD-001) is only in a phase 2a trial, and the company has never completed large-scale or pivotal trials [sec_mda · as of 2026-04-17].
- History of losses — The company has a history of incurring substantial net losses and expects these to continue and increase [sec · filed 2026-04-17].
What to watch
- Progress of OD-001 in its phase 2a clinical trial [sec_mda · as of 2026-04-17].
- Advancement of OD-002 through IND-enabling studies [sec_mda · as of 2026-04-17].
- Ability to raise additional capital to fund operations and development [sec · filed 2026-04-17].
- Any updates on target selection programs and potential partnering relationships [sec · filed 2026-04-17].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Odyssey Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Odyssey Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
26.5 months
D/E 0.15 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
9 buys · 3 sells (180d)
Runway
Financials
Frequently asked questions
What is the AI investment thesis for Odyssey Therapeutics, Inc.?
Odyssey Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing immunology therapeutics, with its two most advanced programs, OD-001 and OD-002, in phase 2a clinical trials and IND-enabling studies, respectively.
Who is the CEO of Odyssey Therapeutics, Inc.?
Dr. Gary D. Glick Ph.D. is the chief executive officer of Odyssey Therapeutics, Inc. (ODTX).
Where is Odyssey Therapeutics, Inc. headquartered?
Odyssey Therapeutics, Inc. (ODTX) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.